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Background and aims: Malnutrition (under and overnutrition) in paediatric cancer patients during and
after treatment increases short and long-term side-effects; however, factors contributing to malnutrition
and patterns of change in nutritional status are still unclear. The aims were to investigate the prevalence
of malnutrition, patterns of change in nutritional status and factors contributing to malnutrition in
Scottish paediatric cancer patients.
Methods: A prospective cohort study of Scottish children aged <18 years, diagnosed with and treated for
cancer between Aug 2010 and Jan 2014 was performed. Clinical and nutritional data were collected at
deﬁned periods up to 36 months. Measurements of weight and height/length and arm anthropometry
(mid-upper arm circumference (MUAC) and triceps skin-fold thickness (TSF)) were collected. Body
composition was estimated from arm anthropometry using Frisancho's references and bio-electrical
impedance (BIA). Malnutrition was deﬁned according to UK BMI curves; undernutrition (<2.3rd
centile; 2 SD), overweight (85th < 95th centile; þ1.05 SD < 1.63 SD) and obese (95th centile; 1.63
SD). We performed descriptive statistics and multilevel analysis. p < 0.05 was considered statistically
signiﬁcant.
Results: Eighty-two patients [median (IQR) age 3.9 (1.9e8.8) years; 56% males] were recruited. At
diagnosis, the prevalence of undernutrition was 13%, overweight 7% and obesity 15%. TSF identiﬁed the
highest prevalence of undernutrition (15%) and the lowest of obesity (1%). BMI [p < 0.001; 95% CI (1.31
e3.47)] and FM (BIA) [p < 0.05; 95% CI (0.006e0.08)] signiﬁcantly increased after 3 months of treatment,
whilst FFM (BIA) [p < 0.05; 95% CI (0.78 to (0.01))] signiﬁcantly decreased during the ﬁrst three
months and these patterns remained until the end of the study. High-treatment risk signiﬁcantly
contributed to undernutrition during the ﬁrst three months of treatment [p ¼ 0.04; 95% CI (16.8 to
(0.4))] and solid tumours had the highest prevalence of undernutrition [BMI (17%)].
Conclusions: Arm anthropometry (or BIA) alongside appropriate nutritional treatment that targets un-
dernutrition initially and overnutrition at later stages should be implemented in routine clinical practice
of paediatric cancer patients.
Crown Copyright © 2019 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition
and Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Nutrition and Biological Sci-
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es/by-nc-nd/4.0/).1. Introduction
Cancer is the most common disease related cause of childhood
death in the UK [1]. Nonetheless 5-year survival rates have doubled
in the last 40 years reaching 82%; however, this varies depending
on the type of cancer, which ranges from over 90% for standard risk
leukaemia and solid tumours, such as retinoblastoma, to betweenety for Clinical Nutrition and Metabolism. This is an open access article under the CC
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due to more advanced, targeted and intensive therapies, more so-
phisticated technology and the success of medical clinical trials in
combination with a more holistic approach to patient care [2e4].
Consequently, attention is focused on reduction of treatment-
related sequelae during and after therapy [5,6]. This includes
malnutrition, which may affect tolerance of therapy, risk of
comorbidities and survival [5].
At present, there is not a single “gold standard” method that
best assesses nutritional status in ill children [5]. Furthermore,
children with cancer experience oedema, changes in body
composition and tumours can weigh up to 10% of total body
weight [7,8]. Misclassiﬁcation of nutritional status can occur if
weight, height and BMI are used in isolation [7,8]. Measurements
of arm anthropometry including mid-upper arm circumference
(MUAC) and triceps skinfold thickness (TSF) [9,10] as well as
bioelectrical impedance (BIA) [11] allow to estimate body
composition [9,10]. Therefore, for a more comprehensive assess-
ment a combination of anthropometry and body composition
methods have been recommended [6].
Malnutrition is deﬁned as undernutrition, overnutrition and/
or poor growth [12,13] and protein energy malnutrition (PEM)
as reduced fat free mass (FFM), with either low fat mass (FM)
(undernutrition), healthy FM (well-nourished) or high FM
(overnutrition) [14e16]. Malnutrition in paediatric cancer pa-
tients has long been recognised [17e22], yet its management
remains variable [5,19], there are differences in reported prev-
alence and its associations with clinical outcomes are still un-
clear, particularly for overnutrition [6]. Furthermore, most
research has focused on undernutrition with overnutrition
during cancer treatment being largely overlooked [6]. The
prevalence of undernutrition ranges between 0 and 65%
worldwide and between 4 and 15% in developed countries. This
is highest in children diagnosed with solid tumours, which
ranges from 23.5 to 50% at diagnosis to 20e46% in survivorship;
whereas, children diagnosed with haematological malignancies,
mainly Acute Lymphoblastic Leukaemia (ALL), have the lowest
prevalence of undernutrition at all stages (9.5e14%) [6]. Finally,
data reporting overnutrition (overweight and obesity) is scarce,
but is more consistent with the methods used to diagnose it
(BMI), and has focused mainly on children diagnosed with
haematological malignancies [6]. Nonetheless, the number of
cases of overnutrition increases from 15% at diagnosis to 38% at
the end of therapy and is most prevalent in children diagnosed
with brain tumours (50%), followed by haematological malig-
nancies (15e40%) and solid tumours (21e35%) [6].
At present, most studies are of retrospective or cross-sectional
nature [6]. The few population based prospective cohort studies
published have focused mainly on children diagnosed with hae-
matological malignancies and most do not report nutritional
status at all stages of treatment [6]. Furthermore, a recent sys-
tematic review [6] emphasised the need to identify when changes
in nutritional status occur and using different forms of measure-
ments in children with cancer for performing population based
longitudinal cohort studies. To date, only one small preliminary
study of this nature has been published in Scotland [23] and one
in the Netherlands [19]. In light of this, our aims were: (i) to
investigate the prevalence of malnutrition in newly diagnosed
paediatric cancer patients and during the study period at deﬁned
time points for 36 months; (ii) to identify changes in anthro-
pometry and body composition during this period; (iii) to deter-
mine both potential factors contributing to malnutrition and (iv)
whether nutritional status (BMI centile) is associated with clinical
outcomes.2. Materials and methods
2.1. Study design, population and time-line
A prospective cohort study was performed. Eligibility criteria
included: children aged <18 years; diagnosed with cancer (ICCC-3)
[24] or Langerhans Cell Histiocytosis between Aug-2010 and Feb-
2014; attending the South East Scotland regional centre for Hae-
matology and Oncology at the Royal Hospital for Sick Children
(RHSC), Edinburgh or Ninewells Hospital, Dundee and patients
were recruited consecutively. We excluded children who were
treated with palliative intent. Childrenwere recruited continuously
during the study period andweremonitored for amaximumperiod
of 36 months and a minimum of 3 months. Measurements were
obtained at baseline, 3, 6, 9 and 12 months and every 6 months
thereafter by two trained researchers in clinic or on the ward.
Anonymised control datawere obtained frommedical records of
patients who met the eligibility criteria but did not consent to the
study. This was done to establish whether the cohort was repre-
sentative of the SE Scottish paediatric oncology population.
2.2. Demographics and clinical parameters
Clinical data (diagnosis, treatment protocol and length of
treatment) and demographic data (age, gender, ethnicity and so-
cioeconomic deprivation) were collected from medical notes.
Clinical outcome was classiﬁed as “event free survival” or “event”
(relapse, death, new metastasis or becoming palliative during the
study period). Treatment intensity was classiﬁed low, medium and
high according to Kazak et al. [25]. As a proxy marker for socio-
economic deprivation of individuals, we used the Standard Index of
Multiple Deprivation (SIMD) [26]. The paediatric cancer cohort was
grouped according to the wider deﬁnition of solid tumours, hae-
matological cancers, brain tumours and other associated diagnoses.
Ethical approval was granted from NHS Scotland (NHS REC 06-
51104-52).
2.3. Measurements of nutritional status and reference values
Measurements of weight and height at the time of diagnosis
(prior to recruitment) were obtained from clinical notes. Following
recruitment, all measurements were taken at each follow up.
Measurements of growth and body composition were repeated
three times.Weight and height (or length for infants<2 years) were
obtained following standard procedures [27]. BMI was calculated
and centiles were obtained from LMS Growth programme [28].
Nutritional status was classiﬁed as underweight (BMI  2.3rd
centile; 2 SD), healthy weight (BMI > 2.3rd to <85th centile;
>2 < þ2 SD), overweight (BMI  85th (þ1.05 SD) and <95th
(<1.63 SD) centile) and obese (95th centile (1.63 SD)) [28,29].
Arm anthropometry [Mid-upper arm circumference (MUAC)
and triceps-skinfold thickness (TSF)] was measured using standard
techniques (Harpended Skinfold caliper) [10]. Data were expressed
as centiles using Frisancho reference values [10,30]. The crude
measures of TSF (mm) and MUAC (mm) were used to calculate
upper arm muscle area (UAMA) and upper arm fat area (UAFA)
using the Frisancho equation and centiles [9]. All references were
adjusted for age and gender and deﬁnitions of malnutrition (MUAC,
TSF, UAMA and UAFA) were: undernutrition  5th centile [8,10,31],
overnutrition  85th to <95th centile and obesity  95th centile
[9,10]. Protein energy malnutrition was deﬁned as UAMA  5th
centile [10] with/without high fat mass (BMI  85th centile) in
children older 1 year old as per reference [9,32,33]. The prevalence
of undernutrition was established using BMI, MUAC and TSF and
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tiles categories) were normalised by calculating the percentage of
the 50th centile.
The percentage of fat mass (FM) and fat free mass (FFM) was
measured using a calibrated SF-BIA Quantum II RJL System (fre-
quency 50 kHz) following manufacturer's instructions. The esti-
mation of FM and FFM was calculated using Schaefer et al. [34,35]
total body water equation and the reference values used were
Fomon et al. [36,37] for children < 10 years old and Wells et al. [37]
for children aged 10e18 years.
The intra and inter-observer technical error of measurement
(TEM) for skin folds and arm circumferences were calculated and
expressed as cm and percentages. All were below the proposed
accreditation for level 2 post-course anthropometrists [38]; MUAC
(intra TEM cm (%) observer 1¼0.12 (0.6%); observer 2¼ 0.11 (0.3%);
inter TEM 2.78 (1.70)%) and TSF (intra TEM observer 1¼0.17 (1.3%);
observer 2 ¼ 0.13 (1.23%); inter TEM 2.83 (1.69%)).
2.4. Dietary intake and nutritional treatment
Total energy intake (TEI) was assessed using a 24 h multi-pass
recall method [39] to establish patterns of change throughout the
study period. This was analysed in WinDiets® (Univation Ltd 2005)
programme [40]. Nutritional treatment was prescribed according to
Subjective Global assessment by the multidisciplinary team and
consisted of enteral ± parenteral nutrition. Estimated total energy
requirements (TER) were calculated using the Henry equation [41]
and a low physical activity level (PAL) of 10th centile [19,42]. TEI
and estimated TER were compared. Data were then normalised by
calculating the percentage of TEI from the TER.
2.5. Statistical analyses
The Statistical Package for Social Science (IBM-SPSS for Win-
dows Statistics, version 19) was employed to analyse all data.
Parametric test and mean (±SD) were used for normally distrib-
uted data and non-parametric tests and median (IQR) for non-
normally distributed data. The agreement between FM% ob-
tained from arm anthropometry and SF-BIA was calculated to
account for discrepancies between these two methods. Descrip-
tive statistics were used to evaluate the prevalence of malnutri-
tion and changes in growth and body composition at deﬁned time
points for 36 months (aim i); To establish patterns of change in
growth (BMI and HFA centiles) and body composition (FFM and
FM established by arm anthropometry and BIA) over time a
multilevel growth model was used (aim ii). All diagnostic criteria
were analysed altogether (p > 0.05). Changes in growth and body
composition have been presented at 0e3, 0e9 and 0e18 time
intervals due to the statistically signiﬁcant differences found in
the variables' trajectories at these time points. To establish factors
that may contribute to changes in nutritional status, established
using BMI centile (primary outcome), at each time point (0e3
months, 0e9 months and 0e18 months) the mixed multilevel
model was used (aim iii). The following factors were tested:
diagnostic criteria, treatment risk, age at diagnosis, nutritional
treatment and TEI. Factors were tested one at the time and only
those that reached a relaxed signiﬁcance of 0.1 were included in
the conditional model. No multilevel analysis was performed after
18 months due to the reduced sample size. Univariate associations
between demographic, clinical and nutritional data and clinical
outcomes (event free survival or event) were established by c2-
test (aim iv). Results were expressed as 95% CI and odds ratios.
p < 0.05 was considered statistically signiﬁcant.
We followed the STROBE guidelines for the presentation of our
data [43].3. Results
3.1. Demographic and clinical characteristics
179 patients were diagnosed with paediatric cancer between
Aug 2010 and Feb 2014. Of these 78 (43%) were excluded (Fig.1) and
101 (57%) were considered eligible. 82 (81%) were recruited, whilst
19 (19%) refused to participate mainly due to stress. Demographic
and clinical characteristics of the population are presented in
Table 1 and the patient's accrual (Fig.1) and follow up (Fig. 2). There
were no statistically signiﬁcant differences between the paediatric
cancer cohort and the paediatric cancer controls (refusals). BMI
centiles of males and females from our paediatric cancer cohort did
not differed at any time point. Twenty-four treatment protocols
were used to treat the paediatric cancer cohort, the median time
follow-up was 312 (IQR 123.5e653.2) days and the time between
diagnosis and baseline measurements was 15.5 (IQR 10.0e25.0)
days and between the start of cancer treatment and baseline
measurements was 9.5 (IQR 6.0e19.5) days. All patients were
receiving cancer treatment when the measurements were taken at
baseline.
At the end of the study (May 2014), the survival rate was 90%
(74), the death rate was 10% (8) and the event free survival rate was
85% (70). Thus 15% (12) of patients had “events” (relapse, cancer
metastasis or did not respond to treatment). Of these, 67% (8/12)
died, 17% (2/12) continued treatment with palliative intent, 17% (2/
12) were receiving second-line treatment by the end of the study, of
whom 8% (1/12) survived.
55 (67%) patients were referred to the Dietitian for nutritional
assessment during the study. The reasons for referral were: un-
dernutrition/weight loss (16/55; 25%), reduced oral intake (10/55;
18%), temporary gut failure (10/55; 18%), to prevent weight loss (7/
55; 13%), dysphagia (4/55; 7%), steroid induced diabetes (2/55; 4%),
mucositis (1/55; 2%) and following parent's request (1/55; 2%). Of
these, 50 (61%) were prescribed some form of nutritional support
and 5 (6%) had general dietary advice. In total, 14/50 (28%) patients
received oral nutritional support (ONS), 17/50 (34%) naso-gastric
tube feeding (NG), 4/50 (8%) percutaneous endoscopic gastro-
stomy feeding (PEG), 1/50 (2%) total parenteral nutrition (TPN) and
15/50 (30%) advanced nutritional support (NS/PEG and TPN).
Mean percentage TEI of individual TER (TEI% of TER) throughout
the study period was 161% (±42%) and this was consistently higher
than TER at all stages apart from the 3months follow up, which was
lower [82% (±51%)]. TEI% of TER ranged between 155% (±78%) at
baseline to 182% (±84%) at 9 months and patients on nutritional
support (152% ± 14%) had similar TEI% of TER than patients who
were not (157% ± 17%) throughout the study period (p¼ 0.4; 95% CI
168 to 60). FM% obtained from arm anthropometry and SF-BIA
had a mean difference of 0.09% (95% CI 1.0 to 1.2).
3.2. Prevalence of malnutrition
The prevalence of malnutrition (undernutrition, overweight and
obesity) varied at each time point and with each measurement
(Fig. 2). Undernutrition was highest at diagnosis and baseline than
at any other time during the study period. At this stage, it ranged
between 13% [BMI (11/81) and MUAC (10/79)] and 15% [TSF (11/
75)]. According to BMI, there were no undernourished patients at 9,
12 and 18 months; however, MUAC and TSF identiﬁed between 3
and 6% at these time points. No patient was undernourished at the
end of the study period (30 and 36 months). Overweight ranged
between 7 and 21% during the study period and both BMI and TSF
identiﬁed similar prevalence at baseline, 3, 6, 18 and 24 months;
however, this differed from each other at 9 and 12 months with
differences of 7% and 21% respectively. Overweight was highest at
Fig. 1. Flow diagram showing patient's accrual.
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Finally, BMI identiﬁed consistently higher prevalence of obesity
than TSF throughout the study period and there were no obese
patients at 36 months. Obesity was least prevalent at diagnosis
[BMI; 12/82 (15%) and TSF; 1/75 (1%)] and most prevalent at 30
months [BMI; 4/12 (33%) and TSF; 3/12 (25%)].
Table 2 shows that children diagnosed with solid tumours had
the highest prevalence of undernutrition. In contrast, patients with
brain tumours and other associated diagnoses had the highest
prevalence of overweight and obesity.
PEM (established using UAMA) was prevalent in all paediatric
cancer diagnoses during the ﬁrst 24 months of the study (Fig. 3
left), particularly at 3 (6/62, 10%) and 24 months (3/24, 12.5%),
whilst no patient was classiﬁed as PEM at either 30 or 36 months.
Fig. 3 right shows the prevalence of malnutrition identiﬁed by UAFA
in all paediatric cancer patients. Undernutrition was highest at
baseline (9/64, 14%) and decreased over time, whereas the number
of both overweight and obesity patients increased from 4% (3/64) at
baseline to 8% (1/12) overweight and 25% (3/12) obese patients.
Furthermore, UAMA and BMI did not classify patients in the same
nutritional status category between 3months and 24months of the
study and a considerable number of PEM (UAMA) patients were
also classiﬁed by BMI as well-nourished, overweight and one obese
(Table 3).
3.3. Patterns of change in anthropometry and body composition
Fig. 4 shows changes in median (IQR) BMI (4 left) and HFA (4
right) centiles. BMI of paediatric cancer patients increased steadily
from the time of diagnosis [48 (19.0e84.5)] until the 30month time
point [85 (39e98)]. Children diagnosed with solid tumours had
consistently lower BMI centiles than the other diagnostic criteria;
however this was not statistically signiﬁcantly different (p < 0.05).
HFA of all paediatric cancer patients was above the 50th centile [55
(26.5e74.0)] at diagnosis and this decreased at every stage until itreached a nadir at 6 months [41 (23.0e64.0)]. From this point, HFA
increased steadily until it reached a peak at 30 months [69.5
(47.7e93.7)]. Children diagnosed with solid tumours had the
highest HFA at the time of diagnosis [62 (25e76)] and baseline
[62.5 (35.5e79.7)], whilst those diagnosed with haematological
malignancies had the lowest HFA centiles at baseline [36
(17.5e36.0)]. This group remained with the lowest HFA centiles for
24 months, at which point it increased considerably reaching the
70th centile (IQR 32e86.9) and levelling with the other cancer
groups.
Fig. 5(a and b) illustrates that MUAC and UAMA both remained
consistent; however, FFM% estimated from both arm anthropom-
etry and BIA decreased marginally during the study (Fig. 5c). In
contrast, TSF, UAFA and FM% (estimated from arm anthropometry
and BIA) all increased during this time (Fig. 5 a, b and d).
Multilevel growth model (Table 4) showed a statistically sig-
niﬁcant increase in mean BMI centile from 0 to 3 months (1.5th
centile; 95% CI 1.31e3.47; p < 0.001) and from 0 to 18 months
(19.0th centile; 95% CI 1.31e3.47; p < 0.001). There were no sta-
tistically signiﬁcant changes in mean HFA centile at any time in-
terval. There were not statistical signiﬁcant changes in either FFM
or FM established using arm anthropometry, apart from the 0e3
months' time interval where there was a signiﬁcant reduction in
the percentage of FFM (0.9%; 95% CI 1.6 to 0.5; p < 0.01). In
contrast, the percentage of FFM established using a BIA decreased
signiﬁcantly between 0 and 3 months (1.71%; 95% CI 0.78
to 0.01; p < 0.05) and 0e9 months (2.83%; 95% CI 0.13
to 0.01; p < 0.02).
3.4. Factors contributing to changes in nutritional status (BMI
centile)
Factors contributing to changes in BMI centile between 0 and
3 months (intercept: estimate 48.4; df 79; 95% CI 41e55;
p < 0.001), 0e9 months (estimate 44.13; df 296; 95% CI
Table 1
Characteristics of the n ¼ 82 Paediatric Oncology cohort and n ¼ 22a controls (non-participants).
Patients' characteristics Cohort Controls p
Median IQR 95% CI Median IQR 95% CI
Age at diagnosis (years) 3.88 1.96e8.83 4.69e6.88 6.52 3.91e10.65 5.37e9.26 0.06c
BMI centile 44.00 12.50e80.50 27.90e65.41 45.00 4.90e70.00 20.01e54.98 0.2c
N % N %
Gender 0.5d
Male 46 56 10 45.5
Female 36 44 12 54.5
Diagnostic criteria 0.9e
Solid tumours 39 47 10 45.5
Haematological malignancies 36 43 11 50
Brain tumours 7 8.5 1 4.5
Other associated diagnosis 4 5 0 5
Diagnosis ICCC-3
I e Leukaemias 35 43 11 50
ALL 29 35 11 50
AML 3 4 0 0
CML 2 2 0 0
HLH 1 1 0 0
II e Lymphoma 10 12 3 14
III e CNS tumour 5 6 2 9
IV e Neuroblastoma 6 7 2 9
V e Retinoblastoma 2 2 0 0
VI e Renal tumour 6 7 0 0
VII e Hepatic tumours 1 1 0 0
VIII e Malignant bone tumours 4 5 3 14
IX e Soft tissue sarcoma 5 6 1 4
X e Germ cell tumours 1 1 0 0
XI e Malignant epithelial neoplasm 4 5 0 0
XII e Others and unspeciﬁed malignant neoplasms 0 0 0 0
Other associated diagnosis 3 4 0 0
LCH 3 4 0 0
Intensity of treatment 0.9d
Low 18 22 4 18
Medium 30 37 8 36
High 34 41 10 46
Socioeconomic statusb 0.6d
I 15 18 7 32
II 12 15 2 9
III 15 18 2 9
IV 24 29 8 36
V 15 18 3 14
Ethnicity 0.5e
White 80 98 21 95.5
Non-white 2 2.4 1 4.5
LCH: Langerham's cell histiocytosis.
a N ¼ 22: 19 (refused to participate) þ 3 (met criteria but were not approached as advised by consultants).
b Socio-economic status (SES) IeV where I denotes the most deprived and V the economically most advantageous families.
c ManneWhitney.
d Chi square test.
e Fisher's exact test.
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CI 34.7e109.5; p < 0.01) were tested in the ﬁxed model. Be-
tween 0 and 3 months, diagnostic criteria (estimate 8.1; df 75;
95% CI 0.41 to 1.1; p < 0.04), treatment risk (estimate 16.5;
df 75; 95% CI 24.3 to 8.6; p < 0.001) and TEI (estimate 0.02;
df 51; 95% CI 0.002e0.2; p ¼ 0.02) all contributed to changes in
BMI centile. Both diagnostic criteria (solid tumours) and high
treatment risk contributed to a decreased in BMI centile,
whereby TEI contributed to an increased in BMI centile during
this period. No single factor contributed to changes in BMI
centile between 0 and 9 months or 0e18 months; however,
nutritional support (estimate 14.3; df 32; 95% CI 2.3 to 31;
p ¼ 0.09) was further tested in the conditional model (relaxed p
value of 0.1) between 0 and 18 months. The conditional model
showed that only high treatment risk contributed to a decreased
in BMI centile (estimate 8.6; df 67; 95% CI 16.8 to 4.0;
p ¼ 0.04) during the ﬁrst 3 months of treatment (Fig. S1).3.5. Associations between nutritional status at diagnosis and
clinical outcome
Only undernutrition (<2.3rd centile) at diagnosis was statistically
signiﬁcantly associated with “event” (relapse, death or becoming
palliative) [Fisher's Exact test (19.901; p < 0.001)]. Furthermore,
patients who were undernourished at diagnosis were 14 times more
likely to have an event (RR ¼ 14). Of these 67% (7/11) were treated
with a high treatment intensity protocol and 17% (4/11) with either
medium or low treatment intensity protocols. Overnutrition (over-
weight and obesity) at diagnosis was not statistically signiﬁcantly
associated with event [Fisher Exact test (7.10; p ¼ 0.3)]
4. Discussion
This is the ﬁrst prospective cohort study investigating the prev-
alence of malnutrition, patterns of change in nutritional status and
Fig. 2. Patient's follow up at each time point and number of patients having had each type of measurement taken. *Drop outs due to: deceased patients, palliative treatment,
treatment given in centres other than RHSC, Edinburgh and Ninewells Hospital, Dundee and patients who missed appointments.
Table 2
Prevalence of malnutrition according to BMI and TSF and stratiﬁed by type of cancer.
Time line Nutritional status Solid tumours Haematological malignancies Brain tumours OADa
BMI TSF BMI TSF BMI TSF BMI TSF
% N % N % N % N % N % N % % N
Baseline Undernutrition 17b 35 18 33 11b 36 12 33 14b 7 17 6 0 4 0 4
Overweight 0 9 5.5 9 28.5 0 0 25
Obesity 8.5 0 14 0 28.5 17 50b 0
3 Months Undernutrition 12.5 32 3 31 3 35 6 32 0 5 0 5 0 3 25 3
Overweight 3 13 14 9 60b 0 0 0
Obesity 5 3 14 6 20 20 33 0
6 Months Undernutrition 0 24 0 22 4 23 5 20 0 3 33b 3 0 4 0 4
Overweight 8.3 9 17 25 33b 0 0 0
Obesity 8.3 13 26 15 33b 33b 25 0
12 Months Undernutrition 0 16 0 16 0 19 0 17 0 3 0 3 e 0 33b 3
Overweight 6 19 42b 23.5 33b 33b e 0
Obesity 0 0 21 23.5 0 e 0
24 Months Undernutrition 12.5b 8 0 7 0 14 0 14 e 0 e 0 e 0 e 0
Overweight 0 14 14 7 e e e e
Obesity 12.5 28.5 28.5 26 e e e e
30 Months Undernutrition 0 5 0 5 0 6 0 6 0 1 0 1 e 0 e 0
Overweight 0 0 33 33 0 0 e e
Obesity 20 20 50 33 0 100 e e
a OAD: other associated diagnoses (N ¼ 4; Langerham's cell histiocytosis).
b c2-test; p < 0.05 against undernutrition, overweight and obesity UK prevalence (DH 2012).
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cancer patients from Scotland. Our results show that undernutrition
was highest during the initial phases of treatment and no child was
undernourished at the end. In contrast, overnutrition increased over
time. Children diagnosed with solid tumours exhibited the highest
prevalence of undernutrition; whereas, overnutrition was highest in
brain tumours and in other associated diagnoses (LCH). Overall BMI
and FM% (BIA) signiﬁcantly increased at 3 and 18 months and at 3
and 9months respectively; whilst FFM% (BIA) signiﬁcantly decreased
at 3 and 9 months. High treatment risk signiﬁcantly contributed to
undernutrition during the ﬁrst 3 months of treatment and under-
nutrition at diagnosis was signiﬁcantly associated with an event
(relapse, becoming palliative or death).4.1. Prevalence of malnutrition in paediatric cancer patients
Undernutrition ranged between 13 and 15% in newly diagnosed
patients. This is in line with a recent a systematic review [6], but
higher than that reported in the Netherlands (8%) [19]. Our results
also showed that undernutrition decreased over time and that no
patient was undernourished at the end of the study. This is
consistent with ﬁndings from elsewhere [44], but contrast with a
systematic review, which reported high prevalence of undernutri-
tion (20%) at the end of treatment [6]. The higher prevalence of
undernutrition at diagnosis is not surprising and likely to be
multifactorial in origin. This can be the result of tumour burden
(with the consequent increase in total energy expenditure
Fig. 3. Prevalence of malnutrition in paediatric cancer patients. Left. Prevalence of undernutrition according to BMI (<2.3rd centile), MUAC (<5th centile) and TSF (<5th centile) in
all cancer diagnoses. 1c2 (9.65), p¼ 0.03; 2c2 (5.274), p ¼ 0.025 against UK prevalence of undernutrition (DH 2012). For BMI, MUAC and TSF n values at different time points see Fig. 1.
Centre. Prevalence of overweight according to BMI (85th centile 95th centile) and TSF (85th to 95th centile) in all cancer diagnoses. For BMI and TSF n values at different time
points see Fig. 1. Right. Prevalence of Obesity at different stages of the disease and according to BMI (>95th centile) and TSF (>95th centile) in all cancers. 1c2-test (5.274), p ¼ 0.03
against UK prevalence of obesity (DH 2012). For BMI and TSF n values at different time points see Table 1.
Table 3
Comparison between children identiﬁed as PEM by UAMA and the nutritional status established by BMI.
Time line UAMA BMI
PEM < 5th C Undernourished < 2.3rd C Well-nourished > 2.3rd < 85th C Overweight  85th < 95th C Obese  95th C
Baseline 3 2 1
3 Months 6 1 4 1
6 Months 4 4
9 Months 3 2 1
12 Months 3 3
18 Months 1 1
24 Months 3 1 1 1
PEM: protein energy malnutrition; UAMA: upper arm muscle area.
Fig. 4. Prevalence (expressed as a percentage) of protein energy malnutrition in paediatric cancer patients during the study period (left) and prevalence of malnutrition established
using UAFA in all paediatric cancer patients at different stages of the disease (right). UAMA: upper arm muscle area; UAFA: upper are fat area.
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initial intensive therapy [18].
In contrast to the Netherlands [19] and data from a recent sys-
tematic review [6], but in agreement with ﬁndings from Canada
[45,46] and Switzerland [47], our study showed a high prevalence of
overweight (8e9%) and obesity (1e14%) in newly diagnosed patients,which increased further to 14e28% (overweight) and 25e33%
(obesity) at later stages. The high prevalence of overnutrition at
diagnosismay be a reﬂection of the high prevalence of obesity seen in
Scottish children; however, overnutrition at later stageswas higher in
paediatric cancer patients than healthy British children [48]. Of note,
the data from later stages should be interpreted with caution due to
Fig. 5. Median BMI centiles (left) and Median Height for Age Centiles (right). Error bars are expressed as IQR.
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others, especially in survivors of childhood cancer [49].
Stratiﬁcation of the data by type of cancer revealed results
consistent with most studies [6,19]. Children diagnosed with solid
tumours (17e22%) exhibited the highest prevalence of undernu-
trition (17e22%) followed by brain tumours (9e17%) and haema-
tological malignancies (3e12%) during the initial phases of
treatment. In contrast, overweight and obesity were highest in OAD
(LCH) (0e25% vs. 0e50%) and brain tumours (0e28.5% vs.
17e28.5%), also at the start of treatment. Comparison of these re-
sults with other studies is difﬁcult due to the paucity of evidence
looking at overnutrition in brain tumours and in children LCH [6].
Overweight and obesity increased during the course of treatment
in all type of cancers, particularly in haematological malignancies
and brain tumours. Therefore, our study suggests that current
nutritional practices have become very successful at treating un-
dernutrition; however, overnutrition has largely been overlooked
and consequently left untreated. This may in part be attributed to
current local nutrition policies, reduced number of specialist
Oncologist/Haematologist Dietitians, who have to prioritise un-
dernutrition, and the inexistence of speciﬁc clinical nutritional
guidelines for the management of paediatric cancer.
4.2. Patterns of change in anthropometry and body composition
Analogous to ﬁndings from the Netherlands [19], our study
showed that BMI and FM (measured with both arm anthropometryand BIA) increased signiﬁcantly at 3 months. Interestingly, BMI had
a second signiﬁcant increment at 18 months, whilst FM attained
signiﬁcance at 9 months. In contrast, FFM declined signiﬁcantly at 3
and 9 months when this was assessed using BIA. During this initial
period of increase in BMI and FM, HFA centiles decreased signiﬁ-
cantly. Like Brinksma et al. [19], our study highlights that changes
in anthropometry and body composition occur early on in paedi-
atric cancer patients. Our study adds that both the increasing trend
of BMI and FM and the reducing trend in FFM continued for 36
months and these changes persist into adulthood [50]. The conse-
quences of reduced FFM during treatment include poor linear
growth, loss of muscle strength, reduced tolerance of therapy and
an increased in both treatment side-effects and infections risk [51].
Furthermore, the reduced FFM accompanied by high BMI and FM in
survivorship increases cardiovascular risk proﬁle in later life, more
so than in the general population [2].
Current Scottish National Paediatric Oncology Dietetic Practices
base their nutritional assessments on either weight for height or
weight only. Although, rapid weight loss is an indicator for acute
undernutrition, this measurement alone does not estimate body
composition or PEM. Furthermore, the equations used in current
paediatric oncology clinical practice to estimate TER take into
consideration growth and a physical activity level (PAL) of 25th
centile [41,48]. Our study, like others [6], has demonstrated that
there is a stagnation of linear growth, especially in children diag-
nosed with haematological malignancies and during the ﬁrst 3
months of treatment. Moreover, there is evidence of a sedentary
Table 4
Mean changes in nutritional status established in 3, 9 and 18 months intervals.
Growth 0e3 Months 0e9 Months 0e18 Months
Change 95% CI p Value Change 95% CI p Value Change 95% CI p Value
BMI C 1.5 1.31e3.47 <0.001 15.9 0.1 to 0.2 0.6 19 1.31e3.47 <0.001
HFA C 1.3 5.9 to 0.04 0.05 3.9 0.4 to 0.02 0.07 4.2 0.005 to 0.24 0.06
Body composition
FFM% AA 0.9% 1.6 to (0.5) <0.001 4.1% 0.09 to 0.06 0.7 4.87% 0.01 to 0.02 0.7
FFM% BIA 1.71% 0.78 to (0.01) <0.05 2.83% 0.13 to (0.01) <0.02 3.88% 0.01 to 0.01 0.8
FM% AA 1.92% 0.01 to 0.02 0.8 5.22% 0.06 to 0.08 0.7 5.98% 0.01 to 0.02 0.8
FM% BIA 1.71% 0.006e0.077 <0.05 3.1% 0.01e0.1 <0.02 3.9% 0.01 to 0.01 0.4
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factors might contribute to an overestimation of TER, which in turn
may lead to overnutrition.
Consistent with a systematic review [6], we have clearly shown
a discrepancy in identifying malnutrition between the different
measurements. Arm anthropometry classiﬁed consistently more
children as undernourished; whereas BMI identiﬁed a higher
prevalence of obesity during the initial phases of treatment, which
may reﬂect the limitations of BMI [5]. Although inaccuracies can
arise from arm anthropometry, the intra- and inter-TEM of TSF and
MUAC were minimal and unlikely to have contributed to these
discrepancies. SF-BIA can be inﬂuenced by dramatic weight
changes and hydration. Nonetheless, FFM% and FM% results from
arm anthropometry and SF-BIA followed the same trajectories and
revealed good limits of agreement. An alternative to SF-BIA is a
multi-frequency BIA, which would address these limitations [11].4.3. Factors contributing to changes in nutritional status (BMI
centile) and associations between nutritional status and clinical
outcome
Treatment risk was the most important factor contributing to
changes in BMI during the ﬁrst 3 months of treatment. High risk
treatment protocols contributed to an increased risk of undernu-
trition, whereas low treatment risk protocols contributed to an
increased in overnutrition. These ﬁndings have also been supported
by others [18]. Importantly, TEI and diagnostic criteria contributed
to changes in BMI when these were analysed independently.
Like others [52], undernutrition at diagnosis was signiﬁcantly
associated with an event and 14 times more likely to have an event
than their well-nourished and overnourished counterparts. When
severity of disease was also considered, most undernourished
children were receiving high risk treatment protocols, suggesting
that nutritional status is likely to be affected by both severity of
disease and treatment risk and that children in high risk treatment
protocols are more likely to be undernourished at diagnosis and to
relapse, become palliative or to die. Undoubtedly, more research is
warranted to conﬁrm these ﬁndings.
Our ﬁndings have several clinical implications. Firstly, we highly
recommend themonitoring of both growth and body composition by
using either arm anthropometry or BIA. By adopting these measures,
the excessive accumulation of fat in the adipose tissue could be
identiﬁed earlier and dietary advice including TEI could be tailored
accordingly. The muscle wasting would also be detected at an early
stage.Whilst somedegreeofmusclewasting resulting from the initial
acute phase response is inevitable [5], attempts should be made to
minimise this at such critical stages. This could be achieved by
increasing protein and introducing physical activity, especially when
side-effects have improved [19]. Finally, in viewof the vulnerability of
children treated with high risk protocols, they should be targeted to
prevent or reduce the risk of undernutrition during the initial 3
months;whilst carefulmatching of TER and TEI and closemonitoringshouldbeperformed topreventoverfeeding. It is essential thateasy to
useanduptodateNationalGrowthCharts forarmanthropometryand
body composition are developed for clinical implementation and
training implemented to improve accuracy of measurements.
4.4. Limitations of the study and future research
The reduced sample size at later stages of the study precluded
considering factors contributing to malnutrition beyond 18
months. The arm anthropometry reference ranges are based on
date frommany years ago; nonetheless, it is the only one that offers
a full reference for children between the ages of 0e18 [10] and 1e18
years [9]. The assessment of physical activity by means of acceler-
ometers proved too challenging for patients and their families.
Future studies should use practical methods such as validated
physical activity questionnaires, which are less accurate, but have
proved more successful [19]. Future research should include high
quality multicenter and international population based prospective
cohort studies that are better able to identify patterns of change in
different type of paediatric cancers and at later stages. In order to
reduce the prevalence of malnutrition and to improve short and
long-term outcomes, clinical guidelines speciﬁcally designed for
nutritional screening, monitoring and management of paediatric
cancer patients are urgently needed. Finally, high quality clinical
trials should incorporate the effects of nutritional treatments and
physical activity on the short and long term effects of nutritional
status and clinical outcome.
5. Conclusions
In conclusion, our results highlight that children diagnosed and
treated for cancer are at high risk of undernutrition and PEM,
particularly during the initial 3 months of treatment, and over-
nutrition at later stages. The single most important factor contrib-
uting to undernutrition during the ﬁrst 3 months of treatment was
high treatment risk. Furthermore, no other clear factors assessed in
this study contributed to malnutrition at later stages and under-
nutrition was associated with poorer clinical outcomes. Impor-
tantly, we recommend the use of arm anthropometry and BIA to all
paediatric cancer patients during treatment at a minimum of 3
months intervals initially and every 6 months thereafter to prevent
malnutrition.
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